Product Description: Pdpe 1.3 is a peptide inhibitor, The main activity is to destroy the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). By interfering with this interaction, PDpep1.3 restores the degradation function of the endocytosomes and lysosomes, thereby reducing alpha-synuclein levels and protecting dopaminergic neurons from alpha-synuclein mediated degradation. Pdpe 1.3 can be used in the study of neurodegenerative diseases and protein-protein interactions[1].
Applications: Neuroscience-Neurodegeneration
Formula: C59H101N17O22
References: [1]Nim S, et al. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease[J]. Nature Communications, 2023, 14(1): 2150.
Molecular Weight: 1400.53
Research Area: Neurological Disease; Others
Target: α-synuclein